La cadena de opciones muestra datos clave de las opciones de acciones de Intelligent Living a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Intelligent Living..

Intelligent Living (NASDAQ:ILAG) Bolsa, Cadena de Opciones

Intelligent Living

Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.

Intelligent Living Application Group Inc. - Ordinary Shares

Intelligent Living Application Group Inc

HC Wainwright &amp; Co. analyst Amit Dayal maintains Eve Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>) with a Buy and raises the price target from $6 to $8.

News

Price Target

Analyst Ratings

EVEX

HC Wainwright & Co. Maintains Buy on Eve Holding, Raises Price Target to $8

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 15.66% on an annualized basis producing an average annual return of 26.71%. Currently, Veeva Systems has a market capitalization of $46.53 billion. 
Buying $1000 In VEEV: If an investor had bought $1000 of VEEV stock 10 years ago, it would be worth $10,519.39 today based on a price of $286.00 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749487514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

VEEV

Here's How Much $1000 Invested In Veeva Systems 10 Years Ago Would Be Worth Today

Ohmyhome Shares Resume Trade

Shares of Cameco Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) soared on Monday, trading up over 11% at $67.29 by late morning. The move higher followed the company&#8217;s announcement of a substantial expected boost to its earnings from its equity stake in Westinghouse Electric Company.
What To Know: Cameco, which holds a 49% interest in Westinghouse, <a href="https://www.benzinga.com/pressreleases/25/06/b45825614/cameco-reports-expected-increase-in-its-share-of-westinghouse-2025-adjusted-ebitda">revealed</a> it anticipates an approximate $170 million increase in its share of Westinghouse&#8217;s adjusted EBITDA for the second quarter and full year of 2025. 
This positive financial revision is directly linked to Westinghouse&#8217;s role as a subcontractor in the construction of two new nuclear reactors at the Dukovany power plant in the Czech Republic.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45841062/rocket-lab-ast-spacemobile-shares-are-surging-monday-whats-fueling-the-move">Rocket Lab, AST SpaceMobile Shares Are Surging Monday: What&#8217;s Fueling The Move?</a>
In addition to the immediate EBITDA uplift in 2025, Cameco <a href="https://www.benzinga.com/pressreleases/25/06/b45825614/cameco-reports-expected-increase-in-its-share-of-westinghouse-2025-adjusted-ebitda">expects</a> long-term financial benefits for Westinghouse through the duration of the Dukovany project, including the provision of fuel fabrication services for both reactors for a specified period.
This development is a significant return on investment for Cameco and its partner, Brookfield Renewable Partners, which owns the remaining 51% of Westinghouse. Despite this one-time boost, the long-term outlook for Westinghouse&#8217;s compound annual growth rate for adjusted EBITDA is maintained at a steady 6% to 10% over the next five years. 
The news was met with strong investor confidence Monday morning, reflected in the heavy trading volume of over 9.5 million shares, double the 100-day average.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45838486/apples-wwdc-2025-kicks-off-today-whats-going-on">Apple&#8217;s WWDC 2025 Kicks Off Today: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy CCJ Stock</h2>
By now you're likely curious about how to participate in the market for Cameco &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CCJ has a 52-week high of $68.12 and a 52-week low of $35.00.
Image: AI Generated

Cameco (CCJ) Stock Surges 11% On Westinghouse Nuclear Deal: What's Going On?

Live On CNBC, Stephanie Link Announces Sold The Home Depot, Inc.

WIIM

VVPR

VivoPower International shares are trading higher after the company announced the date for its special dividend distributions related to the Tembo transactions.

UBER

Live On CNBC, Stephanie Link Announces Bought Uber Technologies

REGN

Regeneron Pharmaceuticals shares are trading higher. A company executive reportedly said the 23andMe auction process was recently reopened and that the tariff situation is not "material" to the business.

Insider Trades

PLUG

Plug Power Form4 Filing Shows Paul B Middleton Bought 650,000 Shares At An Average Price Of $1.03/Share

Ohmyhome Shares Halted On Circuit Breaker To The Upside, Stock Now Up 92.2%

Morgan Stanley analyst Matthew Cost maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Overweight and raises the price target from $420 to $460.

Morgan Stanley Maintains Overweight on AppLovin, Raises Price Target to $460

The U.S. Food and Drug Administration (FDA) sent a &#8220;refusal to file&#8221; letter to Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) on Monday regarding its AXS-14 (esreboxetine) treatment <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">of fibromyalgia</a>.
The FDA states that upon preliminary review, the New Drug Application (NDA) was not sufficiently complete to <a href="https://www.benzinga.com/pressreleases/25/06/g45832920/axsome-therapeutics-provides-update-on-the-new-drug-application-nda-for-axs-14-for-the-management-" target="_blank" rel="noreferrer noopener">permit a substantive review</a>.
Fibromyalgia is a chronic disorder characterized by widespread pain, fatigue, disturbed sleep, depression, and cognitive impairment.
Approximately 17 million Americans, 90% of whom are women, are estimated to suffer from fibromyalgia.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44587826/axsomes-solriamfetol-fails-primary-goal-in-depression-study-but-shows-improvements-in-associated-sleep-disorder" rel="noreferrer noopener">Axsome&#8217;s Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder</a>
Specifically, the FDA does not consider the second of the two placebo-controlled trials in the submission adequate and well-controlled because its primary endpoint was at 8 weeks, and it used a flexible-dose paradigm.
The FDA indicated that the first of the two placebo-controlled trials in the submission, which utilized a 12-week endpoint and a fixed-dose paradigm, is adequate and well-controlled.
The FDA did not raise any questions relating to the positive results of the studies, both of which met their primary endpoints.
To address the FDA&#8217;s feedback, Axsome will conduct an additional controlled trial. As requested by the FDA, this trial will use a fixed-dose paradigm and a 12-week primary endpoint. Axsome anticipates initiating this trial in the fourth quarter of 2025.
Axsome CEO Herriot Tabuteau said the company is &#8220;well positioned to initiate a new controlled trial that will incorporate the FDA&#8217;s feedback by the end of 2025.&#8221;
While the RTF is disappointing, William Blair had ascribed only $3.38 for the AXS-14 fibromyalgia program to total $199.98 sum-of-the-parts fair value in the model.
With the requirement for an additional study, analyst Myles Minter has delayed the launch of AXS-14 in the model to the second half of 2028 and now ascribes $1.89 for the program to the fair value.
Investor focus remains on the Alzheimer's disease agitation (AD-A), which is on track for the third quarter of 2025.
After talking with the company's management, William Blair said they believe the recent Refusal to File (RTF) is limited to the Division of Anesthesiology, Addiction Medicine, and Pain Medicine and the fibromyalgia program.
It should not impact the separate submission for AXS-05 in Alzheimer's disease agitation, which will go through the Psychiatry division in Q3 2025. 
The firm added that getting a PDUFA date for this application, supported by the ADVANCE and ACCORD studies, and possibly receiving priority review due to its breakthrough therapy status, would be a key milestone and help reduce concerns about FDA-related delays caused by its internal restructuring.
Price Action: AXSM stock is down 0.60% at $111.24 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/02/43790716/axsomes-axs-05-in-alzheimers-agitation-could-be-billion-dollar-opportunity-says-analyst" target="_blank" rel="noreferrer noopener">Axsome&#8217;s AXS-05 In Alzheimer&#8217;s Agitation Could Be Billion Dollar Opportunity, Says Analyst</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Health Care

General

AXSM

FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required

Morgan Stanley analyst John Glass downgrades McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) from Overweight to Equal-Weight and lowers the price target from $329 to $324.

Downgrades

Morgan Stanley Downgrades McDonald's to Equal-Weight, Lowers Price Target to $324

Academy Sports and Outdoors, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) will release its first-quarter financial results before the <a href="https://www.benzinga.com/quote/ASO">opening bell on Tuesday, June 10.</a>
Analysts expect the Katy, Texas-based company to report quarterly earnings at 89 cents per share, down from $1.08 per share in the year-ago period. Academy Sports and Outdoors projects quarterly revenue of $1.37 billion, compared to $1.36 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On June 6, Academy Sports and Outdoors declared a quarterly cash dividend of 13 cents per share.
Academy Sports and Outdoors shares gained 2% to trade at $44.31 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/aso/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Citigroup analyst Paul Lejuez maintained a Buy rating and cut the price target from $60 to $55 on June 4, 2025. This analyst has an accuracy rate of 64%.</li>
<li>UBS analyst Michael Lasser maintained a Neutral rating and slashed the price target from $54 to $48 on June 4, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Wells Fargo analyst Ike Boruchow maintained an Equal-Weight rating and raised the price target from $38 to $43 on May 14, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Evercore ISI Group analyst Greg Melich maintained an In-Line rating and cut the price target from $54 to $53 on April 1, 2025. This analyst has an accuracy rate of 81%.</li>
<li>JP Morgan analyst Christopher Horvers maintained a Neutral rating and raised the price target from $52 to $54 on March 21, 2025. This analyst has an accuracy rate of 71%</li>
</ul>
Considering buying ASO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ASO/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="407" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09123435/image-121-1024x407.png" alt="" class="wp-image-943539" style="width:577px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09123435/image-121-1024x407.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09123435/image-121-300x119.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09123435/image-121-768x305.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09123435/image-121.png 1501w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/45835438/top-3-financial-stocks-that-may-collapse-in-june">Top 3 Financial Stocks That May Collapse In June</a> </li>
</ul>
Photo via Shutterstock

Markets

Top Wall Street Forecasters Revamp Academy Sports and Outdoors Expectations Ahead Of Q1 Earnings

Morgan Stanley analyst Erin Wright initiates coverage on Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Overweight rating and announces Price Target of $364.

Initiation

Morgan Stanley Initiates Coverage On Molina Healthcare with Overweight Rating, Announces Price Target of $364

Morgan Stanley analyst Ricky Goldwasser initiates coverage on Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight rating and announces Price Target of $70.

Morgan Stanley Initiates Coverage On Centene with Overweight Rating, Announces Price Target of $70

NCPL

Netcapital shares are trading higher following the announcement that its portfolio company, Zelgor, has completed the acquisition of Mixie.

Morgan Stanley analyst Alexandra Steiger downgrades Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) from Overweight to Equal-Weight and lowers the price target from $346 to $280.

LULU

Morgan Stanley Downgrades Lululemon Athletica to Equal-Weight, Lowers Price Target to $280

SCHW

The Schwab Trading Activity Index Decreased To 39.68 In May, Down From Its Score Of 41.18 In April

Morgan Stanley analyst Dara Mohsenian reiterates Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) with a Overweight and maintains $81 price target.

Reiteration

Morgan Stanley Reiterates Overweight on Coca-Cola, Maintains $81 Price Target

Contracts

Press Releases

Intelligent Living Application Group Inc. Announces Strategic Cooperation with Artificial Intelligence Assisted Robotic Research Firm in Hong Kong

Intelligent Living Application Group Inc. Regains Compliance with Nasdaq's Minimum Bid Price Rule

Earnings

Intelligent Living Application Group Inc. Announces First Half 2024 Unaudited Financial Results

Intelligent Living Application Group Inc. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Intelligent Living Application Group Inc. Announces Pricing of $600,000 Public Offering of Ordinary Shares

Offerings

Intelligent Living Application Group Inc. Announces Closing of $600,000 Public Offering of Ordinary Shares

Intelligent Living Application Group Inc. Announces the Launch of its Smart Lock to Play a Role in $4.95 Billion Market

Comments

Intelligent Living

Intelligent Living (ILAG) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL